Atrial Fibrillation
Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress
Published in Cardiovascular Business Week, September 8th, 2009
Results of the Phase III RE-LY (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran)(1) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).(1)
Atrial fibrillation affects approximately 2.3 million Americans(2) and can increase the risk of stroke five-fold.(3) Top-line findings from the 18,113 patient RE-LY...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
More Articles from Cardiovascular Business Week
- Angiology
IDEV(R) Technologies Announces First Patient Enrolled in Multi-Center Clinical Trial of SUPERA(R) PERipheral Stent - Aortic Stenosis
Ochsner Replaces Heart Valve Without Open Heart Surgery - BioEDEN
Banking on Baby Teeth: - Bioengineering
ATS Medical Announces FDA Approval for a Landmark Clinical Investigation of the ATS 3f Aortic Bioprosthesis - Cancer
Country Legend Naomi Judd Joins 'Partners Against Pain' - Cardiology
Boston Scientific Announces Schedule for European Society of Cardiology Congress - More from this issue of Cardiovascular Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
